Ronda E. Stryker Sells 190,000 Shares of Stryker Co. (NYSE:SYK) Stock

Stryker Co. (NYSE:SYK) Director Ronda E. Stryker sold 190,000 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total value of $61,457,400.00. Following the completion of the sale, the director now directly owns 3,316,608 shares of the company’s stock, valued at approximately $1,072,790,023.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Stryker Trading Up 2.0 %

Shares of Stryker stock traded up $6.39 on Thursday, hitting $325.99. 1,006,696 shares of the company’s stock traded hands, compared to its average volume of 1,335,059. The firm’s 50-day moving average price is $337.71 and its two-hundred day moving average price is $339.89. The stock has a market capitalization of $124.23 billion, a PE ratio of 37.30, a price-to-earnings-growth ratio of 2.49 and a beta of 0.89. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.79 by $0.02. The company had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.54 EPS. On average, research analysts expect that Stryker Co. will post 11.99 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Monday, September 30th. Stryker’s dividend payout ratio is currently 36.53%.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of analyst reports. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, July 11th. Royal Bank of Canada restated an “outperform” rating and set a $386.00 price target on shares of Stryker in a research note on Wednesday, July 31st. TD Cowen lifted their price objective on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 11th. The Goldman Sachs Group started coverage on Stryker in a report on Thursday, May 30th. They set a “neutral” rating and a $372.00 price objective on the stock. Finally, Truist Financial decreased their price objective on Stryker from $364.00 to $345.00 and set a “hold” rating on the stock in a report on Thursday, August 1st. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $373.11.

Institutional Trading of Stryker

A number of large investors have recently made changes to their positions in SYK. Norges Bank bought a new stake in shares of Stryker in the 4th quarter valued at $1,260,562,000. Global Assets Advisory LLC bought a new stake in shares of Stryker in the 1st quarter valued at $341,049,000. JPMorgan Chase & Co. increased its position in shares of Stryker by 10.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company’s stock valued at $3,096,078,000 after buying an additional 813,311 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Stryker by 5.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,541,845 shares of the medical technology company’s stock worth $3,755,782,000 after purchasing an additional 642,178 shares in the last quarter. Finally, 1832 Asset Management L.P. increased its holdings in Stryker by 146.9% during the 1st quarter. 1832 Asset Management L.P. now owns 878,669 shares of the medical technology company’s stock worth $314,449,000 after purchasing an additional 522,817 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.